India's medical technology market is expected to grow to $35 billion by 2030, supported by rising domestic demand and expanding exports. Exports are forecast to double to $8 billion, though the country continues to rely on imports for high-end surgical and electro-medical equipment.
The Indian medical technology industry is entering a phase of rapid expansion, with projections suggesting the market could reach $35 billion by 2030. According to a report by Bain & Company, this growth is supported by a mix of strong internal healthcare needs and the increasing global reach of Indian-manufactured medical devices.
Scaling Domestic and Global Presence
India has established itself as a key participant in the Asian medical technology landscape. The Asia-Pacific region is projected to see its demand reach $132 billion by 2030, with India serving as a significant driver of this growth. During the 2025 fiscal year, India recorded medical device exports totaling $4 billion. Industry estimates now suggest that these exports could climb to $8 billion by 2030, growing at a yearly rate of over 20%.
Companies are already making inroads into international markets. For example, Poly Medicure currently provides medical supplies to more than 125 countries, while Wipro GE has a presence in approximately 70 nations. This global footprint indicates that Indian manufacturers are successfully balancing affordability with the scalability required to meet international standards.
The Challenge of High-End Imports
While export growth is a positive signal for the sector, the industry still faces a dependency on foreign technology for complex needs. India currently spends $5.5 billion annually on importing high-end electro-medical and surgical equipment. This highlights a clear gap in the domestic market, where Indian firms are primarily competitive in accessible, cost-effective solutions but have yet to capture a larger share of the advanced, high-value manufacturing segment.
Future Growth Triggers
The ability of Indian companies to bridge the gap between basic, affordable innovation and high-end manufacturing will be a major factor for investors to track. Success in this area will likely depend on several operational factors, including the ability to build stronger clinical evidence for new products, the depth of regulatory expertise, and the effectiveness of commercialization strategies within both domestic and international healthcare systems. Investors may watch how companies navigate the shift toward more complex medical equipment and whether they can successfully lower the country's reliance on high-end imports while maintaining profit margins in a competitive global environment.